FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Maslowski John Michael
2. Issuer Name and Ticker or Trading Symbol

Fibrocell Science, Inc. [ FCSC ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO
(Last)          (First)          (Middle)

FIBROCELL SCIENCE, INC., 405 EAGLEVIEW BOULEVARD
3. Date of Earliest Transaction (MM/DD/YYYY)

12/13/2019
(Street)

EXTON, PA 19341
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/13/2019  D  3164 D$3 (1)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock $232.5 12/13/2019  D     908   (2)1/14/2021 Common Stock 908.0  (2)0 D  
Option to Purchase Common Stock $82.35 12/13/2019  D     1167   (2)7/19/2023 Common Stock 1167.0  (2)0 D  
Option to Purchase Common Stock $74.25 12/13/2019  D     1334   (2)1/17/2024 Common Stock 1334.0  (2)0 D  
Option to Purchase Common Stock $44.1 12/13/2019  D     1334   (2)5/13/2024 Common Stock 1334.0  (2)0 D  
Option to Purchase Common Stock $52.95 12/13/2019  D     6668   (2)1/20/2025 Common Stock 6668.0  (2)0 D  
Option to Purchase Common Stock $34.05 12/13/2019  D     6667   (2)3/1/2026 Common Stock 6667.0  (2)0 D  
Option to Purchase Common Stock $9.94 12/13/2019  D     16667   (2)12/16/2026 Common Stock 16667.0  (2)0 D  
Option to Purchase Common Stock $3.45 12/13/2019  D     20000   (2)1/25/2028 Common Stock 20000.0  (2)0 D  
Option to Purchase Common Stock $1.78 12/13/2019  D     100000   (2)4/12/2029 Common Stock 100000.0  (2)0 D  

Explanation of Responses:
(1) Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
(2) Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Maslowski John Michael
FIBROCELL SCIENCE, INC.
405 EAGLEVIEW BOULEVARD
EXTON, PA 19341
X
CEO

Signatures
/s/ John M. Maslowski12/13/2019
**Signature of Reporting PersonDate

Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Fibrocell Science Charts.
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Fibrocell Science Charts.